ADAR1 Capital Management’s Voyager Therapeutics VYGR Stock Holding History

ADAR1 Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$135K	Hold	35,000	–	–	0.01%	278
2025 Q4	$138K	Hold	35,000	–	–	0.01%	240
2025 Q3	$163K	Sell	35,000 -44,945	-56%	-$163K	0.02%	187
2025 Q2	$249K	Buy	79,945 +4,400	+6%	+$14.2K	0.04%	148
2025 Q1	$255K	Sell	75,545 -51,247	-40%	-$239K	0.05%	135
2024 Q4	$719K	Buy	126,792 +86,158	+212%	+$555K	0.14%	94
2024 Q3	$238K	Buy	40,634 +22,000	+118%	+$160K	0.04%	153
2024 Q2	$147K	Sell	18,634 -72,900	-80%	-$611K	0.03%	155
2024 Q1	$852K	Sell	91,534 -94,360	-51%	-$797K	0.19%	66
2023 Q4	$1.57M	Buy	+185,894	New	+$1.35M	0.56%	35

Other funds holding VYGR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ADAR1 Capital Management's VYGR Position: Q1 2026 in Review

ADAR1 Capital Management held its Voyager Therapeutics (VYGR) position steady in Q1 2026 at 35,000 shares worth $135K. The position accounts for 0.01% of the portfolio, ranked #278.

ADAR1 Capital Management first reported a position in VYGR in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.57M in Q4 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

ADAR1 Capital Management held 35,000 shares of Voyager Therapeutics worth $135K as of Q1 2026.
ADAR1 Capital Management left its Voyager Therapeutics share count unchanged in Q1 2026.
Voyager Therapeutics made up 0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #278 holding.
ADAR1 Capital Management first reported a position in Voyager Therapeutics in Q4 2023 and has held it in 10 quarters since.
ADAR1 Capital Management's Voyager Therapeutics position peaked at $1.57M in Q4 2023.
135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.